Budget proposal offers big money for nursing homes, elder care in Ohio … Louisiana legislators consider weakening brand new nursing home disaster plan rule … Small and rural providers continue to lag...
Eli Lilly expects Medicare about-face on Alzheimer’s drugs coverage
By
Alicia Lasek
Apr 23, 2023
New data on Lilly’s experimental drug donanemab may influence CMS’s restrictive stance on coverage of this and other amyloid-busting Alzheimer’s treatments, a company executive says.
Also in the News for Tuesday, March 14
By
Kimberly Marselas
Mar 14, 2023
California man, 23, shot to death in nursing home bed, police say … Race, geographic disparities found in 30-day readmissions for people with dementia … On the Move: AMDA Names Michelle Zinnert new...
Patient advocates decry CMS decision on Alzheimer’s drug coverage
By
Alicia Lasek
Feb 24, 2023
The Alzheimer’s Association and others have strongly criticized a decision by CMS to stand by its highly restrictive coverage for new dementia drugs.
Alzheimer’s drug plus clot buster caused brain hemorrhage death: report
By
Alicia Lasek
Jan 06, 2023
A clot-busting drug administered during a stroke helped lead to the death of a patient taking the experimental Alzheimer’s drug lecanemab, a peer-reviewed autopsy analysis has revealed.
Also in the News for Wednesday, Jan. 4
By
Kimberly Marselas
Jan 04, 2023
COVID hospitalizations approach last summer’s high, but flu and RSV cases waning … NC nursing home to pay $126K after storm-related staff shortages, two patient deaths … FDA decision on experimental...
On eve of Alzheimer’s drug decision, Congress critiques FDA for Aduhelm review failures
By
Alicia Lasek
Jan 03, 2023
An “atypical review process and corporate greed” factored into the FDA’s approval of Alzheimer’s drug Aduhelm in 2021, congressional investigators say. They recommend sticking to protocol...
Clinical briefs for Tuesday, January 3
By
Alicia Lasek
Jan 03, 2023
Only two days left to nominate a deserving colleague for a McKnight’s Woman of Distinction 2023 award! … Third death tied to Eisai and Biogen’s experimental Alzheimer’s drug lecanemab … U.S....
Alzheimer’s drug lecanemab has ‘moderate’ effect on cognitive decline, new trial data show
By
Alicia Lasek
Dec 01, 2022
The experimental Alzheimer’s drug slowed decline in memory and thinking by 27% when compared with placebo, although 20% of patients reported adverse events.
Depression drug eases Alzheimer’s agitation; new death in lecanemab trial raises concerns
By
Alicia Lasek
Nov 30, 2022
Two drugs in late-stage clinical trials are making news, one as a potential treatment for agitation, and the other for evidence of bleeding risk.